LUND, Sweden, Sept. 3, 2021 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") announces today that board member Martin Møller purchases 1,056 shares in Immunovia, an investment of a total of SEK 141,295. This is Martin Møller's total holding after the purchase.

For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1.

In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. The European launch plan will be communicated during the second half of 2021.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.                                                              

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/board-member-of-immunovia-purchases-shares-in-the-company,c3409799

The following files are available for download:

https://mb.cision.com/Main/13121/3409799/1464152.pdf

Press release (PDF)

Copyright 2021 PR Newswire

Immunovia Ab (publ) (LSE:0G8X)
Gráfica de Acción Histórica
De Nov 2021 a Dic 2021 Haga Click aquí para más Gráficas Immunovia Ab (publ).
Immunovia Ab (publ) (LSE:0G8X)
Gráfica de Acción Histórica
De Dic 2020 a Dic 2021 Haga Click aquí para más Gráficas Immunovia Ab (publ).